A Study to Assess the Effect of S-600918 on the Pharmacokinetics of Fexofenadine, Rosuvastatin, and Atorvastatin in Healthy Adult Subjects

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224683

Enrollment

Registered

2019-05-15

Start date

2019-05-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

investigational material(s) Generic name etc : S-600918 INN of investigational material : - Therapeutic category code : 222 Antitussives Dosage and Administration for Investigational material : Oral

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy male subjects

Exclusion criteria

Exclusion criteria: Subjects who are considered ineligible for this study by the investigator or subinvestigator due to current or history of significant metabolic or endocrine, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, immune, neurological or psychiatric disorders, or other clinically significant diseases.

Design outcomes

Primary

Measure	Time frame
pharmacokinetics Maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing (AUC0-last), area under the concentration-time curve extrapolated from time zero to infinity (AUC0-inf), terminal elimination half-life (t1/2,z), and terminal elimination rate constant (lambdaz), mean residence time (MRT), apparent total clearance (CL/F), and apparent volume of distribution in the terminal elimination phase (Vz/F)	—

Measure

Time frame

pharmacokinetics Maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing (AUC0-last), area under the concentration-time curve extrapolated from time zero to infinity (AUC0-inf), terminal elimination half-life (t1/2,z), and terminal elimination rate constant (lambdaz), mean residence time (MRT), apparent total clearance (CL/F), and apparent volume of distribution in the terminal elimination phase (Vz/F)

—

Secondary

Measure	Time frame
safety Treatment-emergent adverse events (TEAEs), physical examination, clinical laboratory tests, vital signs, and 12-lead electrocardiograms	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026